REFERENCES
- Chowdary K. P., Srinivasa Rao Sk. Investigation of dissolution enhancement of itraconazole by solid dispersion in superdisintegrants. Drug Dev. Ind. Pharm. 2004; 26: 1207–1211
- Cleary, G. W., Shah, V. P., & Maibach, H. I. (1993). Transdermal Delivery Systems: A Medical Rationale. In Shah, V. P.; Maibach, H. I. (Eds.), Topical Drug Bioavailability, Bioequivalence and Penetration; Plenum Press, New York. [Reprinted from Int. J. Pharm., 236, Murdan, S., Drug delivery to the nail following topical application, 1–26, with permission from Elsevier.]
- Ghannoum M. A., Hajjeh R. A., Scher, et al. A large-scale North American study of fungal isolates from nails: The frequency of Onychomycosis. J. Am. Acad. Dermotol. 2000; 43: 641–648
- Gupta A. K., Konnikov N., MacDonald P., Rich P., Rodger N. W., Edmonds M. W., McManus R., Summerbell R. C., Gupta A. K. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br. J. Dermatol. 1998; 139: 665–671
- http://www.drugs.com/MTM/itraconazole.html Micromedex Physicians Desk Reference, Inc. Version: 7.03. Revision Date: 1/23/04, Copyright 1996–2004 Cerner Multum
- Murdan S. Drug delivery to the nail following topical application. Int. J. Pharm. 2002; 236: 1–26
- Rambali B., Verreck G., Baert L., Massart D. L. Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Dev. Ind. Pharm. 2003; 29: 641–652
- Repka M. A., McGinity J. W., Zhang F., Koleng J. J. Hot-Melt Extrusion Technology. Encyclopedia of Pharmaceutical Technology2nd, J. Swarbrik, J. Boylan. Marcel Dekker, Inc., New York 2002
- Repka M., Mididoddi P., Stodghill S. Influence of human nail etching for the assessment of topical onychomycosis therapies. Int. J. Pharm. 2004; 282: 95–106
- Richardson M., Warnock D. Fungal Infection: Diagnosis and Management3rd. Blackwell Publishing, Oxford 2003
- Six K., Verreck G., Peeters J., Brewster M., Van Den Mooter G. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J. Pharm. Sci. 2004; 93: 124–131